Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 17/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20528861 | 1.00 | FOLH1 (0.49) | FOLH1ALBNOD1 | |
| SCHEMBL19069723 | 0.90 | ALB (0.58) | FOLH1ALB | |
| SCHEMBL23129208 | 0.88 | NOD1 (0.52) | FOLH1NOD1 | |
| SCHEMBL15871482 | 0.86 | FOLH1 (0.43) | FOLH1ALBNOD1 | |
| SCHEMBL14729288 | 0.86 | FOLH1 (0.70) | FOLH1 | |
| SCHEMBL16790748 | 0.84 | ALB (0.42) | FOLH1ALBNOD1 | |
| SCHEMBL18889449 | 0.84 | NOD1 (0.67) | FOLH1NOD1 | |
| SCHEMBL30905812 | 0.84 | NOD1 (0.64) | FOLH1NOD1 | |
| SCHEMBL20528853 | 0.82 | SMN1; SMN2 (0.55) | FOLH1ALBNOD1 | |
| SCHEMBL20528854 | 0.82 | SMN1; SMN2 (0.55) | FOLH1ALBNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | NOVO NORDISK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | NOVO NORDISK A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| EP-3606560-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | Novo Nordisk A/S (DK) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018185131-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | NOVO NORDISK A/S (DK) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | IAPP, IDE, INSR | FOLH1 1170/4885ALB 213/4885NOD1 401/4885 |
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | IAPP, IDE, INSR | FOLH1 1170/4885ALB 213/4885NOD1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.